Fabjan Jure, Koniuszewski Filip, Schaar Benjamin, Ernst Margot
Department of Pathobiology of the Nervous System, Center for Brain Research, Medical University of Vienna, Vienna, Austria.
Front Neurosci. 2021 Jan 15;14:611953. doi: 10.3389/fnins.2020.611953. eCollection 2020.
Pyrazoloquinolinones (PQs) are a versatile class of GABA receptor ligands. It has been demonstrated that high functional selectivity for certain receptor subtypes can be obtained by specific substitution patterns, but so far, no clear SAR rules emerge from the studies. As is the case for many GABA receptor targeting chemotypes, PQs can interact with distinct binding sites on a given receptor pentamer. In pentamers of αβγ composition, such as the most abundant α1β2γ2 subtype, many PQs are high affinity binders of the benzodiazepine binding site at the extracellular α+/γ2- interfaces. There they display a functionally near silent, flumazenil-like allosteric activity. More recently, interactions with extracellular α+/β- interfaces have been investigated, where strong positive modulation can be steered toward interesting subtype preferences. The most prominent examples are functionally α6-selective PQs. Similar to benzodiazepines, PQs also seem to interact with sites in the transmembrane domain, mainly the sites used by etomidate and barbiturates. This promiscuity leads to potential contributions from multiple sites to net modulation. Developing ligands that interact exclusively with the extracellular α+/β- interfaces would be desired. Correlating functional profiles with binding sites usage is hampered by scarce and heterogeneous experimental data, as shown in our meta-analysis of aggregated published data. In the absence of experimental structures, bound states can be predicted with pharmacophore matching methods and with computational docking. We thus performed pharmacophore matching studies for the unwanted sites, and computational docking for the extracellular α1,6+/β3- interfaces. The results suggest that PQs interact with their binding sites with diverse binding modes. As such, rational design of improved ligands needs to take a complex structure-activity landscape with branches between sub-series of derivatives into account. We present a workflow, which is suitable to identify and explore potential branching points on the structure-activity landscape of any small molecule chemotype.
吡唑并喹啉酮(PQs)是一类多功能的GABA受体配体。已经证明,通过特定的取代模式可以获得对某些受体亚型的高功能选择性,但到目前为止,研究中尚未出现明确的构效关系规则。与许多靶向GABA受体的化学类型一样,PQs可以与给定受体五聚体上的不同结合位点相互作用。在αβγ组成的五聚体中,例如最丰富的α1β2γ2亚型,许多PQs是细胞外α+/γ2-界面处苯二氮䓬结合位点的高亲和力结合剂。在那里,它们表现出功能上近乎沉默的、类似氟马西尼的变构活性。最近,人们研究了与细胞外α+/β-界面的相互作用,在那里可以将强正性调节导向有趣的亚型偏好。最突出的例子是功能上α6选择性的PQs。与苯二氮䓬类似,PQs似乎也与跨膜结构域中的位点相互作用,主要是依托咪酯和巴比妥类药物使用的位点。这种多配体性导致多个位点对净调节有潜在贡献。开发仅与细胞外α+/β-界面相互作用的配体是理想的。如我们对汇总的已发表数据的荟萃分析所示,功能谱与结合位点使用情况的关联受到稀缺和异质实验数据的阻碍。在没有实验结构的情况下,可以用药理学匹配方法和计算对接来预测结合状态。因此,我们对不需要的位点进行了药理学匹配研究,并对细胞外α1,6+/β3-界面进行了计算对接。结果表明,PQs以多种结合模式与其结合位点相互作用。因此,合理设计改进的配体需要考虑具有衍生物子系列之间分支的复杂构效关系格局。我们提出了一种工作流程,适用于识别和探索任何小分子化学类型的构效关系格局上的潜在分支点。